Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vimal K Derebail

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Kidney360|June 10, 2021
Should PLEX Be Used for Severe AKI and/or Pulmonary Hemorrhage in ANCA-Associated Vasculitis (AAV)? PROVimal K Derebail
Frontiers in Medicine|October 13, 2022
Editorial: Pathogenesis and management of glomerular diseasesSophia Lionaki, Vimal K Derebail
The New England Journal of Medicine|February 14, 2020
ANCA-Associated Vasculitis - Refining Therapy with Plasma Exchange and GlucocorticoidsVimal K Derebail, Ronald J Falk
Clinical Journal of the American Society of Nephrology : CJASN|July 27, 2023
Sparsentan and the Expanding Landscape of IgA Nephropathy TreatmentVimal K Derebail, Patrick H Nachman
Hematology. American Society of Hematology. Education Program|January 18, 2011
Sickle-cell trait: novel clinical significanceNigel S Key, Vimal K Derebail
Expert Review of Hematology|October 20, 2017
The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle traitRakhi P Naik, Vimal K Derebail
Hematology/Oncology Clinics of North America|November 18, 2022
Sickle Cell Disease and the Kidney: Filters Gone AwryJeffrey D Lebensburger, Vimal K Derebail
British Journal of Haematology|March 11, 2015
Negative health implications of sickle cell trait in high income countries: from the football field to the laboratoryNigel S Key, Philippe Connes, Vimal K Derebail
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 26, 2019
Glomerular Filtration: Too Much of a Good Thing?Amy K Mottl, Thomas H Hostetter, Vimal K Derebail
Kidney360|May 31, 2023
Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal ManifestationsMofiyin Obadina, Sam Wilson, Vimal K Derebail, et al.
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Kidney360|June 10, 2021
Should PLEX Be Used for Severe AKI and/or Pulmonary Hemorrhage in ANCA-Associated Vasculitis (AAV)? PROVimal K Derebail
Frontiers in Medicine|October 13, 2022
Editorial: Pathogenesis and management of glomerular diseasesSophia Lionaki, Vimal K Derebail
The New England Journal of Medicine|February 14, 2020
ANCA-Associated Vasculitis - Refining Therapy with Plasma Exchange and GlucocorticoidsVimal K Derebail, Ronald J Falk
Clinical Journal of the American Society of Nephrology : CJASN|July 27, 2023
Sparsentan and the Expanding Landscape of IgA Nephropathy TreatmentVimal K Derebail, Patrick H Nachman
Hematology. American Society of Hematology. Education Program|January 18, 2011
Sickle-cell trait: novel clinical significanceNigel S Key, Vimal K Derebail
Expert Review of Hematology|October 20, 2017
The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle traitRakhi P Naik, Vimal K Derebail
Hematology/Oncology Clinics of North America|November 18, 2022
Sickle Cell Disease and the Kidney: Filters Gone AwryJeffrey D Lebensburger, Vimal K Derebail
British Journal of Haematology|March 11, 2015
Negative health implications of sickle cell trait in high income countries: from the football field to the laboratoryNigel S Key, Philippe Connes, Vimal K Derebail
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 26, 2019
Glomerular Filtration: Too Much of a Good Thing?Amy K Mottl, Thomas H Hostetter, Vimal K Derebail
Kidney360|May 31, 2023
Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal ManifestationsMofiyin Obadina, Sam Wilson, Vimal K Derebail, et al.
Pageof 11